WASHINGTON, D.C. (Friday, February 11, 2011) - The Biotechnology Industry Organization (BIO) today announced that President and CEO James C. Greenwood will ring the closing bell at The NASDAQ Stock Market on February 15, 2011 together with numerous executives representing the life science industry. This ceremony concludes the 13th Annual BIO CEO & Investor Conference – the largest independent investor conference focused on publicly-traded biotechnology companies. Over 200 US biotech companies are listed on the NASDAQ exchange.
“BIO applauds NASDAQ’s efforts to serve the biotech community. Given that the great majority of publicly listed US biotech companies list on the NASDAQ, the NASD has a strong understanding of the needs of rapidly growing, innovative companies,” said BIO President and CEO James C. Greenwood. “In addition, NASDAQ’s recent proposal to develop its new BX market will considerably expand financing opportunities for small companies. Expanding investor interest in biotech companies that do not meet current listing criteria is a move that will help a substantial number of biotech companies.”
The NASDAQ Stock Market has proposed the development of a new Venture Market, known as the BX, intended to assist small companies to become publicly traded, thereby greatly expanding their capital financing opportunities. The reduced quantitative listing parameters for participation in the BX opens the door for many companies in need of financing that would otherwise be shut out. The BX also is intended serve as a landing market for companies who have been delisted from a national securities exchange.
The biosciences are one of the fastest growing industry segments in the United States - employing more than 1.3 million people engaged in the research and development of pioneering therapies, medical devices, improved agricultural products and practices as well as alternative energy production processes and industrial products. The U.S. Department of Labor projects that this industry will grow at an average annual rate of 1.5 percent between 2008 and 2018.
The 13th Annual BIO CEO & Investor Conference will feature presentations from more than 140 emerging and established public biotech companies and non-profit funding organizations. The program will also include a number of therapeutic workshops featuring CSOs, MDs and industry analysts discussing new therapies and the latest areas of pipeline innovation in rheumatology, urology, psychiatry and oncology.
To learn more about the 13th Annual BIO CEO & Investor Conference , including registration and up-to-date program information, please visit http://www.bio.org/bioceo. Registration is complimentary for qualified investors and credentialed members of the media.
About the 13th Annual BIO CEO & Investor Conference
The BIO CEO & Investor Conference is a must attend event for institutional investors, industry analysts, and senior biotechnology executives focused on shaping the future investment landscape of the biotechnology industry. BIO is pleased to recognize the leadership provided by the BIO CEO & Investor Conference sponsors, including Lead Bank Sponsor Wedbush PacGrow Life Sciences, Host Bank Sponsor Rodman & Renshaw LLC, and Supporting Bank Sponsors BMO Capital Markets, Deutsche Bank, Lazard and Roth Capital Partners.